FDA Warns That Topical Pain-Relief Products Containing CBD Violate FD&C Act
By EsqSocial Corporation 24/03/21
This week, the U.S. Food and Drug Administration (FDA) issued Warning Letters that effectively declare that the presence of cannabidiol (CBD) as an inactive ingredient in topical over-the-counter (OTC) drug products is a violation of the federal Food, Drug, And Cosmetic Act (FD&C Act)......
By: Rivkin Radler LLP